BRCA2 inhibition enhances cisplatin-mediated alterations in tumor cell proliferation, metabolism, and metastasis

Molecular Oncology

Volumn 8, Issue 8, 2014, Pages 1429-1440

  Rytelewski, Mateusz ^a   Tong, Jessica G ^a   Buensuceso, Adrian ^a   Leong, Hon S ^a   Maleki Vareki, Saman ^a   Figueredo, Rene ^a   Di Cresce, Christine ^a   Wu, Sherry Y ^b   Herbrich, Shelley M ^b   Baggerly, Keith A ^b   Romanow, Larissa ^a   Shepherd, Trevor ^a   Deroo, Bonnie J ^a   Sood, Anil K ^b   Chambers, Ann F ^a   Vincent, Mark ^a   Ferguson, Peter J ^a,c   Koropatnick, James ^a,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

BRCA2; Cisplatin; DNA repair; Drug sensitization; Metabolism; Metastasis

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BRCA2 PROTEIN; CISPLATIN; GLUCOSE; ANTISENSE OLIGONUCLEOTIDE; RAD51 PROTEIN;

A549 CELL LINE; ANTISENSE THERAPY; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER RESISTANCE; CANCER SURVIVAL; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; CELL RESPIRATION; CHORIOALLANTOIS; CONTROLLED STUDY; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; DRUG POTENTIATION; DRUG SENSITIZATION; EMBRYO; ENDOMETRIUM CARCINOMA; FEMALE; GENE MUTATION; GLUCOSE TRANSPORT; GLYCOLYSIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; METASTASIS; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CARCINOMA; OVERALL SURVIVAL; ANIMAL; CELL LINE; CHICK EMBRYO; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ANIMALS; BRCA2 PROTEIN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CHICK EMBRYO; CISPLATIN; HUMANS; NEOPLASM METASTASIS; OLIGORIBONUCLEOTIDES, ANTISENSE; RAD51 RECOMBINASE;

EID: 84911964818     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.05.017     Document Type: Article

References (32)

1. Aguilera A., Garcia-Muse T. Causes of genome instability. Annu. Rev. Genet. 2013, 47:1-32.
2. Alborzinia H., Can S., Holenya P., Scholl C., Lederer E., Kitanovic I., Wolfl S. Real-time monitoring of cisplatin-induced cell death. PLoS One 2011, 6:e19714.
3. Arpaia E., Blaser H., Quintela-Fandino M., Duncan G., Leong H.S., Ablack A., Nambiar S.C., Lind E.F., Silvester J., Fleming C.K., Rufini A., Tusche M.W., Brustle A., Ohashi P.S., Lewis J.D., Mak T.W. The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene 2012, 31:884-896.
4. Ashworth A. Drug resistance caused by reversion mutation. Cancer Res. 2008, 68:10021-10023.
5. Bayraktar S., Gutierrez-Barrera A.M., Lin H., Elsayegh N., Tasbas T., Litton J.K., Ibrahim N.K., Morrow P.K., Green M., Valero V., Booser D.J., Hortobagyi G.N., Arun B.K. Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin. Exp. Metastasis 2013, 30:631-642.
6. Burrell R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
7. Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474:609-615.
8. Cresce C., Way C., Rytelewski M., Vareki S.M., Nilam S., Vincent M.D., Koropatnick J., Ferguson P.J. Antisense technology: from unique laboratory tool to novel anticancer treatments. From Nucleic Acids Sequences to Molecular Medicine 2012, 145-189. Springer Berlin Heidelberg. V.A. Erdmann, J. Barciszewski (Eds.).
9. Cvetkovic D., Dragan M., Leith S.J., Mir Z.M., Leong H.S., Pampillo M., Lewis J.D., Babwah A.V., Bhattacharya M. KISS1R induces invasiveness of estrogen receptor-negative human mammary epithelial and breast cancer cells. Endocrinology 2013, 154:1999-2014.
10. Egawa C., Miyoshi Y., Taguchi T., Tamaki Y., Noguchi S. High BRCA2 mRNA expression predicts poor prognosis in breast cancer patients. Int. J. Cancer 2002, 98:879-882.
11. Egawa-Takata T., Endo H., Fujita M., Ueda Y., Miyatake T., Okuyama H., Yoshino K., Kamiura S., Enomoto T., Kimura T., Inoue M. Early reduction of glucose uptake after cisplatin treatment is a marker of cisplatin sensitivity in ovarian cancer. Cancer Sci. 2010, 101:2171-2178.
12. Ferguson P.J., Currie C., Vincent M.D. Enhancement of platinum-drug cytotoxicity in a human head and neck squamous cell carcinoma line and its platinum-resistant variant by liposomal amphotericin B and phospholipase A2-II. Drug Metab. Dispos 1999, 27:1399-1405.
13. Gao J., Aksoy B.A., Dogrusoz U., Dresdner G., Gross B., Sumer S.O., Sun Y., Jacobsen A., Sinha R., Larsson E., Cerami E., Sander C., Schultz N. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6:pl1.
14. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
15. Hao J., Madigan M.C., Khatri A., Power C.A., Hung T.T., Beretov J., Chang L., Xiao W., Cozzi P.J., Graham P.H., Kearsley J.H., Li Y. Invitro and invivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147. PLoS One 2012, 7:e40716.
16. Holt J.T., Toole W.P., Patel V.R., Hwang H., Brown E.T. Restoration of CAPAN-1 cells with functional BRCA2 provides insight into the DNA repair activity of individuals who are heterozygous for BRCA2 mutations. Cancer Genet. Cytogenet. 2008, 186:85-94.
17. James E., Waldron-Lynch M.G., Saif M.W. Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature. Anticancer Drugs 2009, 20:634-638.
18. Jeong S.M., Xiao C., Finley L.W., Lahusen T., Souza A.L., Pierce K., Li Y.H., Wang X., Laurent G., German N.J., Xu X., Li C., Wang R.H., Lee J., Csibi A., Cerione R., Blenis J., Clish C.B., Kimmelman A., Deng C.X., Haigis M.C. SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell 2013, 23:450-463.
19. Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., Shen H., Robertson A.G., Pashtan I., Shen R., Benz C.C., Yau C., Laird P.W., Ding L., Zhang W., Mills G.B., Kucherlapati R., Mardis E.R., Levine D.A. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73.
20. Lee W., Jiang Z., Liu J., Haverty P.M., Guan Y., Stinson J., Yue P., Zhang Y., Pant K.P., Bhatt D., Ha C., Johnson S., Kennemer M.I., Mohan S., Nazarenko I., Watanabe C., Sparks A.B., Shames D.S., Gentleman R., de Sauvage F.J., Stern H., Pandita A., Ballinger D.G., Drmanac R., Modrusan Z., Seshagiri S., Zhang Z. The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature 2010, 465:473-477.
21. Martin L.P., Hamilton T.C., Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 2008, 14:1291-1295.
22. Maxwell K.N., Domchek S.M. Cancer treatment according to BRCA1 and BRCA2 mutations. Nat. Rev. Clin. Oncol. 2012, 9:520-528.
23. Monneret C. Platinum anticancer drugs. From serendipity to rational design. Ann. Pharm. Fr. 2011, 69:286-295.
24. Pleasance E.D., Cheetham R.K., Stephens P.J., McBride D.J., Humphray S.J., Greenman C.D., Varela I., Lin M.L., Ordonez G.R., Bignell G.R., Ye K., Alipaz J., Bauer M.J., Beare D., Butler A., Carter R.J., Chen L., Cox A.J., Edkins S., Kokko-Gonzales P.I., Gormley N.A., Grocock R.J., Haudenschild C.D., Hims M.M., James T., Jia M., Kingsbury Z., Leroy C., Marshall J., Menzies A., Mudie L.J., Ning Z., Royce T., Schulz-Trieglaff O.B., Spiridou A., Stebbings L.A., Szajkowski L., Teague J., Williamson D., Chin L., Ross M.T., Campbell P.J., Bentley D.R., Futreal P.A., Stratton M.R. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
25. Russnes H.G., Navin N., Hicks J., Borresen-Dale A.L. Insight into the heterogeneity of breast cancer through next-generation sequencing. J.Clin. Invest. 2011, 121:3810-3818.
26. Rytelewski M., Ferguson P.J., Maleki Vareki S., Figueredo R., Vincent M., Koropatnick J. Inhibition of BRCA2 and thymidylate synthase creates multidrug sensitive tumor cells via the induction of combined "complementary lethality". Mol. Ther. Nucleic Acids 2013, 2:e78.
27. Sakai W., Swisher E.M., Jacquemont C., Chandramohan K.V., Couch F.J., Langdon S.P., Wurz K., Higgins J., Villegas E., Taniguchi T. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 2009, 69:6381-6386.
28. Shen D.W., Pouliot L.M., Hall M.D., Gottesman M.M. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 2012, 64:706-721.
29. Vencken P.M., Kriege M., Hoogwerf D., Beugelink S., van der Burg M.E., Hooning M.J., Berns E.M., Jager A., Collee M., Burger C.W., Seynaeve C. Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients. Ann. Oncol. 2011, 22:1346-1352.
30. Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., Collins N., Gregory S., Gumbs C., Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
31. Yang D., Khan S., Sun Y., Hess K., Shmulevich I., Sood A.K., Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011, 306:1557-1565.
32. Yang Z., Schumaker L.M., Egorin M.J., Zuhowski E.G., Guo Z., Cullen K.J. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin. Cancer Res. 2006, 12:5817-5825.